简体
  • 简体中文
  • 繁体中文

热门资讯> 正文

Immutep的Efti与MSG的KEYTRUDA组合在治疗一线颈部癌方面具有良好的安全性

2024-09-16 20:15

  • Results delivered in prestigious Proffered Paper oral presentation at ESMO Congress 2024
  • In patients with any PD-L1 expression (CPS ≥1), efti in combination with KEYTRUDA outperformance is largest in CPS ≥20 with 31.0% ORR (34.5% ORR including partial response after data cut-off) versus 18.5% ORR for KEYTRUDA
  • Efti in combination with KEYTRUDA led to a high durability of response of 17.5 months in patients with any PD-L1 expression and combination continues to have favourable safety profile
  • Statistically significant increase in absolute lymphocyte count biomarker seen in the efti in combination with KEYTRUDA arm shows efti's biological activity in a randomised setting
    • Based on the high unmet need and encouraging results to date, with Overall Survival expected in 2025, the path forward will be discussed with regulatory agencies

风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。